ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2364

CROSS-Sectional Assessment of Damage in Takayasu Arteritis with A Validated Tool

Ahmet Omma1, Burak Erer2, Omer Karadag3, Neslihan Yilmaz4, Fatma Alibaz-Oner5, Fatih Yildiz6, Melike Kalfa7, Gezmis Kimyon8, Sedat Kiraz9, Haner Direskeneli5, Eren Erken10, Kenan Aksu11, Ahmet Mesut Onat12, Ahmet Gul2, Lale Ocal2, Murat Inanc2 and Sevil Kamali13, 1Internal Medicine Department, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, 5Division of Rheumatology, Department of Internal Medicine, Marmara University, Faculty of Medicine, Istanbul, Turkey, 6Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, 7Dept. of Internal Medicine, Division of Rheumatology, Ege University, Faculty of Medicine, Izmir, Turkey, 8Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 9Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 10Rheumatology, Cukurova University School of Medicine, Adana, Turkey, 11Rheumatology, Ege University School of Medicine, Izmir, Turkey, 12Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 13Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Health Assessment Questionnaire, Takayasu.s arteritis and vasculitis

Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis with a chronic course, usually causing damage by the time of diagnosis. To our knowledge, there is no reported study assessing the damage related to TA itself or treatment.We aimed to evaluate the damage cross-sectionally in TA patients with Vasculitis Damage Index (VDI), a generic tool developed for systemic vasculitides.

Methods: A collection of 165 TA patients (146 female) fulfilling ACR criteria and followed-up more than 6 mo from 6 centers in Turkey, were enrolled into the study. All patients underwent detailed examination including eye, vascular imaging, echocardiography and bone dansitometry. Clinical, angiographical and treatment characteristics and damage items of VDI were recorded using a standardized protocol. Disease activity and quality of life (QoL) were evaluated by Kerr criteria and SF-36, respectively. TA patients with persistant disease activity ≥6 mo were considered as resistant.The correlation between VDI scores and disease duration, cumulative glucocorticoid (GC), cyclophosphamide (CYC) duration and doses, and mental (MCS) and physical (PCS) component summary scores of SF-36 were analysed by Pearson correlation test. VDI scores according to the disease resistance and poor QoL (MCS and PCS scores <50) were compared by Mann Whitney U test.

Results: The mean age, follow-up time and disease duration were 40 ± 12 years, 74 ± 73 mo and 95 ± 91 mo, respectively. Type I (51%) was the most common type of vascular involvement. Cumulative doses / duration of GC and CYC were 10,6±9,6 g / 64±60 mo and 2±5,5 g / 2,3±6,5 mo, respectively; 39% of them had resistant course. Major vessel stenosis, absent pulses, claudication were demonstrated in ≥50% of TA patients, as damage items. Osteoporosis (22%) and cataract (12%) were the main treatment related damages. Cumulative VDI scores in TA cohort were found to be 4.3±2.2, mainly (3.8±1.9) due to disease itself. MCS and PCS scores were calculated as 43±10 and 38±11, respectively. Poor SF-36 MCS scores were demonstrated in 70% and PCS scores in 80% of the patients. VDI scores were found to be correlated with disease duration (p<0.01, r= 0.27), cumulative doses of GC (p<0.01, r= 0.29) and CYC (p=0.02, r= 0.20) and duration of GC (p<0.01 r= 0.37). A negative correlation was observed between the VDI and both MCS (p=0.007, r=-0,21) and PCS scores (p<0.001, r=-0.36). The higher VDI scores were detected in the subgroup of patients PCS <50 (4,8±2,2 vs 2,9±1,5, p<0.001).

Conclusion: Cross-sectional analysis of this TA cohort with a long disease duration revealed vascular damage scores comparable to the scores of severe systemic necrotizing vasculitides. Majority of TA patients had disease related damage, characterized by peripheral vascular involvement. The longer disease duration and higher GC and CYC exposure were significantly associated with the damage. The severe damage scores (≥5) were observed in TA patients with poor health quality.


Disclosure:

A. Omma,
None;

B. Erer,
None;

O. Karadag,
None;

N. Yilmaz,
None;

F. Alibaz-Oner,
None;

F. Yildiz,
None;

M. Kalfa,
None;

G. Kimyon,
None;

S. Kiraz,
None;

H. Direskeneli,
None;

E. Erken,
None;

K. Aksu,
None;

A. M. Onat,
None;

A. Gul,
None;

L. Ocal,
None;

M. Inanc,
None;

S. Kamali,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-sectional-assessment-of-damage-in-takayasu-arteritis-with-a-validated-tool/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology